Xeris Biopharma Holdings, Inc. Common Stock (XERS) is a publicly traded Healthcare sector company. As of September 9, 2026, XERS trades at $8.46 with a market cap of $1.56B and a P/E ratio of -84.15. XERS moved +1.24% today. Year to date, XERS is +8.03%; over the trailing twelve months it is +9.14%. Its 52-week range spans $3.15 to $10.08. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces XERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for XERS, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $8.46 |
| Market Cap | $1.56B |
| P/E Ratio | -84.15 |
| EPS | $-0.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.08 |
| 52-Week Low | $3.15 |
| Volume | 162.06K |
| Avg Volume | 0 |
| Revenue (TTM) | $335.41M |
| Net Income | $-17.16M |
| Gross Margin | 0.00% |
5 analysts cover XERS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.